WHO SHOULD CONDUCT MODELING AND COST-EFFECTIVENESS ANALYSIS?

In some countries, reimbursement of drugs is based on cost-effectiveness analysis (CEA), in others not. In times of ageing populations, increasing number of possible interventions, and limited resources, it seems likely that CEA will be more and more important as a basis for decision making.

Saved in:
Bibliographic Details
Published inInternational journal of technology assessment in health care Vol. 30; no. 1; pp. 128 - 129
Main Author Rosen, M
Format Journal Article
LanguageEnglish
Published New York, USA Cambridge University Press 01.01.2014
Subjects
Bias
Corporate sponsorship
Cost analysis
Cost-Benefit Analysis
Decision Making
Drug Utilization - economics
Health technology assessment
Humans
Letters to the Editor
Medicin och hälsovetenskap
Models, Economic
Prescription Drugs - economics
Reimbursement
Systematic review
Technology Assessment, Biomedical
Online AccessGet full text

Cover

More Information
Summary:In some countries, reimbursement of drugs is based on cost-effectiveness analysis (CEA), in others not. In times of ageing populations, increasing number of possible interventions, and limited resources, it seems likely that CEA will be more and more important as a basis for decision making.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0266-4623
1471-6348
1471-6348
DOI:10.1017/S0266462313000755